Aquestive Therapeutics, Inc. (NASDAQ: AQST) Stock Competitors & Peer Comparison
See AQST's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for AQST and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AQST | $3.83 | +1.32% | 480.7M | -5.89 | -$0.65 | N/A |
| TAK | $19.61 | -0.31% | 62.4B | 14.10 | $1.39 | +3.59% |
| TEVA | $41.31 | -0.46% | 48.1B | 14.09 | $2.93 | N/A |
| HLN | $10.14 | +0.10% | 44.6B | 20.77 | $0.49 | +1.95% |
| ZTS | $79.59 | +0.26% | 32.9B | 12.09 | $6.58 | +2.62% |
| VTRS | $18.26 | -2.12% | 21B | 7.25 | $2.52 | +2.64% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $23.49 | -0.25% | 11.7B | 22.15 | $1.06 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| RDY | $13.08 | +0.08% | 10.9B | 27.85 | $0.47 | +0.64% |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
AQST vs TAK Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, TAK has a market cap of 62.4B. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while TAK trades at $19.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas TAK's P/E ratio is 14.10. In terms of profitability, AQST's ROE is +2.44%, compared to TAK's ROE of +0.02%. Regarding short-term risk, AQST is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for AQST.Check TAK's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
AQST vs TEVA Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, TEVA has a market cap of 48.1B. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while TEVA trades at $41.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas TEVA's P/E ratio is 14.09. In terms of profitability, AQST's ROE is +2.44%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, AQST is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for AQST.Check TEVA's competition here
Haleon plc (NYSE: HLN)
AQST vs HLN Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, HLN has a market cap of 44.6B. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while HLN trades at $10.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas HLN's P/E ratio is 20.77. In terms of profitability, AQST's ROE is +2.44%, compared to HLN's ROE of +0.10%. Regarding short-term risk, AQST is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for AQST.Check HLN's competition here
Zoetis Inc. (NYSE: ZTS)
AQST vs ZTS Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, ZTS has a market cap of 32.9B. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while ZTS trades at $79.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas ZTS's P/E ratio is 12.09. In terms of profitability, AQST's ROE is +2.44%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, AQST is more volatile compared to ZTS. This indicates higher risk in terms of short-term price fluctuations for AQST.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
AQST vs VTRS Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, VTRS has a market cap of 21B. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while VTRS trades at $18.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas VTRS's P/E ratio is 7.25. In terms of profitability, AQST's ROE is +2.44%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, AQST is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for AQST.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
AQST vs ITCI Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas ITCI's P/E ratio is -180.64. In terms of profitability, AQST's ROE is +2.44%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, AQST is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for AQST.Check ITCI's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
AQST vs ELAN Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, ELAN has a market cap of 11.7B. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while ELAN trades at $23.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas ELAN's P/E ratio is 22.15. In terms of profitability, AQST's ROE is +2.44%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, AQST is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for AQST.Check ELAN's competition here
Catalent, Inc. (NYSE: CTLT)
AQST vs CTLT Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas CTLT's P/E ratio is -27.84. In terms of profitability, AQST's ROE is +2.44%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, AQST is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for AQST.Check CTLT's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
AQST vs RDY Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, RDY has a market cap of 10.9B. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while RDY trades at $13.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas RDY's P/E ratio is 27.85. In terms of profitability, AQST's ROE is +2.44%, compared to RDY's ROE of +0.09%. Regarding short-term risk, AQST is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for AQST.Check RDY's competition here
Alkermes plc (NASDAQ: ALKS)
AQST vs ALKS Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, ALKS has a market cap of 7.2B. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while ALKS trades at $42.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas ALKS's P/E ratio is 45.23. In terms of profitability, AQST's ROE is +2.44%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, AQST is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for AQST.Check ALKS's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
AQST vs LNTH Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, LNTH has a market cap of 6.5B. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while LNTH trades at $99.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas LNTH's P/E ratio is 16.79. In terms of profitability, AQST's ROE is +2.44%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, AQST is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for AQST.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
AQST vs AMRX Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, AMRX has a market cap of 6.2B. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while AMRX trades at $19.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas AMRX's P/E ratio is 21.51. In terms of profitability, AQST's ROE is +2.44%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, AQST is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for AQST.Check AMRX's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
AQST vs RGC Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, RGC has a market cap of 5B. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while RGC trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas RGC's P/E ratio is -1005.00. In terms of profitability, AQST's ROE is +2.44%, compared to RGC's ROE of -1.61%. Regarding short-term risk, AQST is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for AQST.Check RGC's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
AQST vs INDV Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, INDV has a market cap of 4.2B. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while INDV trades at $33.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas INDV's P/E ratio is 9.28. In terms of profitability, AQST's ROE is +2.44%, compared to INDV's ROE of -2.16%. Regarding short-term risk, AQST is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for AQST.Check INDV's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
AQST vs HCM Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, HCM has a market cap of 2.5B. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while HCM trades at $14.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas HCM's P/E ratio is 137.14. In terms of profitability, AQST's ROE is +2.44%, compared to HCM's ROE of +0.01%. Regarding short-term risk, AQST is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for AQST.Check HCM's competition here
Alvotech (NASDAQ: ALVOW)
AQST vs ALVOW Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, ALVOW has a market cap of 2.4B. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while ALVOW trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas ALVOW's P/E ratio is 37.90. In terms of profitability, AQST's ROE is +2.44%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, AQST is more volatile compared to ALVOW. This indicates higher risk in terms of short-term price fluctuations for AQST.Check ALVOW's competition here
Bausch Health Companies Inc. (NYSE: BHC)
AQST vs BHC Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, BHC has a market cap of 2.4B. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while BHC trades at $6.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas BHC's P/E ratio is 1.62. In terms of profitability, AQST's ROE is +2.44%, compared to BHC's ROE of +0.89%. Regarding short-term risk, AQST is more volatile compared to BHC. This indicates higher risk in terms of short-term price fluctuations for AQST.Check BHC's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
AQST vs SUPN Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, SUPN has a market cap of 2.3B. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while SUPN trades at $39.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas SUPN's P/E ratio is 13.02. In terms of profitability, AQST's ROE is +2.44%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, AQST is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for AQST.Check SUPN's competition here
Perrigo Company plc (NYSE: PRGO)
AQST vs PRGO Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, PRGO has a market cap of 2.2B. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while PRGO trades at $16.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas PRGO's P/E ratio is 6.44. In terms of profitability, AQST's ROE is +2.44%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, AQST is more volatile compared to PRGO. This indicates higher risk in terms of short-term price fluctuations for AQST.Check PRGO's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
AQST vs DCPH Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas DCPH's P/E ratio is -11.58. In terms of profitability, AQST's ROE is +2.44%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, AQST is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for AQST.Check DCPH's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
AQST vs AVDL Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, AQST's ROE is +2.44%, compared to AVDL's ROE of +0.10%. Regarding short-term risk, AQST is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for AQST.Check AVDL's competition here
Embecta Corp. (NASDAQ: EMBCV)
AQST vs EMBCV Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas EMBCV's P/E ratio is N/A. In terms of profitability, AQST's ROE is +2.44%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, AQST is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for AQST.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
AQST vs DVAX Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas DVAX's P/E ratio is -41.89. In terms of profitability, AQST's ROE is +2.44%, compared to DVAX's ROE of +0.09%. Regarding short-term risk, AQST is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for AQST.Check DVAX's competition here
Alvotech (NASDAQ: ALVO)
AQST vs ALVO Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, ALVO has a market cap of 1.8B. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while ALVO trades at $5.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas ALVO's P/E ratio is -8.53. In terms of profitability, AQST's ROE is +2.44%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, AQST is more volatile compared to ALVO. This indicates higher risk in terms of short-term price fluctuations for AQST.Check ALVO's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
AQST vs TRLV Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, TRLV has a market cap of 1.7B. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while TRLV trades at $10.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas TRLV's P/E ratio is -4.18. In terms of profitability, AQST's ROE is +2.44%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, AQST is more volatile compared to TRLV. This indicates higher risk in terms of short-term price fluctuations for AQST.Check TRLV's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
AQST vs ANIP Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while ANIP trades at $72.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas ANIP's P/E ratio is 8.84. In terms of profitability, AQST's ROE is +2.44%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, AQST is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for AQST.Check ANIP's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
AQST vs TARO Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas TARO's P/E ratio is 30.05. In terms of profitability, AQST's ROE is +2.44%, compared to TARO's ROE of +0.03%. Regarding short-term risk, AQST is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for AQST.Check TARO's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
AQST vs PAHC Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, PAHC has a market cap of 1.6B. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while PAHC trades at $39.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas PAHC's P/E ratio is 13.42. In terms of profitability, AQST's ROE is +2.44%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, AQST is more volatile compared to PAHC. This indicates higher risk in terms of short-term price fluctuations for AQST.Check PAHC's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
AQST vs PCRX Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, PCRX has a market cap of 1.4B. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while PCRX trades at $36.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas PCRX's P/E ratio is 13.98. In terms of profitability, AQST's ROE is +2.44%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, AQST is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for AQST.Check PCRX's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
AQST vs ETON Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, ETON has a market cap of 1.4B. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while ETON trades at $49.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas ETON's P/E ratio is 129.50. In terms of profitability, AQST's ROE is +2.44%, compared to ETON's ROE of +0.40%. Regarding short-term risk, AQST is more volatile compared to ETON. This indicates higher risk in terms of short-term price fluctuations for AQST.Check ETON's competition here
Cronos Group Inc. (NASDAQ: CRON)
AQST vs CRON Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while CRON trades at $3.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas CRON's P/E ratio is 16.64. In terms of profitability, AQST's ROE is +2.44%, compared to CRON's ROE of +0.06%. Regarding short-term risk, AQST is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for AQST.Check CRON's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
AQST vs AMPH Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, AMPH has a market cap of 1.1B. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while AMPH trades at $26.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas AMPH's P/E ratio is 8.92. In terms of profitability, AQST's ROE is +2.44%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, AQST is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for AQST.Check AMPH's competition here
Harrow Health, Inc. (NASDAQ: HROW)
AQST vs HROW Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, HROW has a market cap of 1B. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while HROW trades at $27.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas HROW's P/E ratio is -27.96. In terms of profitability, AQST's ROE is +2.44%, compared to HROW's ROE of -1.04%. Regarding short-term risk, AQST is more volatile compared to HROW. This indicates higher risk in terms of short-term price fluctuations for AQST.Check HROW's competition here
PetIQ, Inc. (NASDAQ: PETQ)
AQST vs PETQ Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas PETQ's P/E ratio is 83.73. In terms of profitability, AQST's ROE is +2.44%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, AQST is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for AQST.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
AQST vs COLL Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, COLL has a market cap of 749.1M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while COLL trades at $23.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas COLL's P/E ratio is 2.89. In terms of profitability, AQST's ROE is +2.44%, compared to COLL's ROE of +0.16%. Regarding short-term risk, AQST is more volatile compared to COLL. This indicates higher risk in terms of short-term price fluctuations for AQST.Check COLL's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
AQST vs IRWD Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, IRWD has a market cap of 584.9M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while IRWD trades at $3.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas IRWD's P/E ratio is 4.54. In terms of profitability, AQST's ROE is +2.44%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, AQST is more volatile compared to IRWD. This indicates higher risk in terms of short-term price fluctuations for AQST.Check IRWD's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
AQST vs BDSI Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas BDSI's P/E ratio is 6.82. In terms of profitability, AQST's ROE is +2.44%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, AQST is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for AQST.Check BDSI's competition here
Evotec SE (NASDAQ: EVO)
AQST vs EVO Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, EVO has a market cap of 504.4M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while EVO trades at $1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas EVO's P/E ratio is -2.01. In terms of profitability, AQST's ROE is +2.44%, compared to EVO's ROE of -0.27%. Regarding short-term risk, AQST is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for AQST.Check EVO's competition here
Evolus, Inc. (NASDAQ: EOLS)
AQST vs EOLS Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, EOLS has a market cap of 486.1M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while EOLS trades at $7.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas EOLS's P/E ratio is -23.31. In terms of profitability, AQST's ROE is +2.44%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, AQST is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for AQST.Check EOLS's competition here
Kamada Ltd. (NASDAQ: KMDA)
AQST vs KMDA Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, KMDA has a market cap of 439.1M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while KMDA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas KMDA's P/E ratio is 20.03. In terms of profitability, AQST's ROE is +2.44%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, AQST is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for AQST.Check KMDA's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
AQST vs TKNO Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, TKNO has a market cap of 365.1M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while TKNO trades at $6.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas TKNO's P/E ratio is -21.94. In terms of profitability, AQST's ROE is +2.44%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, AQST is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for AQST.Check TKNO's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
AQST vs TLRY Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, TLRY has a market cap of 338.8M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while TLRY trades at $3.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas TLRY's P/E ratio is -2.16. In terms of profitability, AQST's ROE is +2.44%, compared to TLRY's ROE of -0.09%. Regarding short-term risk, AQST is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for AQST.Check TLRY's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
AQST vs EBS Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, EBS has a market cap of 325.8M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while EBS trades at $6.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas EBS's P/E ratio is 4.41. In terms of profitability, AQST's ROE is +2.44%, compared to EBS's ROE of -0.36%. Regarding short-term risk, AQST is more volatile compared to EBS. This indicates higher risk in terms of short-term price fluctuations for AQST.Check EBS's competition here
Canopy Growth Corporation (NASDAQ: CGC)
AQST vs CGC Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, CGC has a market cap of 302.8M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while CGC trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas CGC's P/E ratio is -1.60. In terms of profitability, AQST's ROE is +2.44%, compared to CGC's ROE of -0.33%. Regarding short-term risk, AQST is more volatile compared to CGC. This indicates higher risk in terms of short-term price fluctuations for AQST.Check CGC's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
AQST vs ALIM Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas ALIM's P/E ratio is 5.28. In terms of profitability, AQST's ROE is +2.44%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, AQST is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for AQST.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
AQST vs LNDC Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas LNDC's P/E ratio is -4.04. In terms of profitability, AQST's ROE is +2.44%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, AQST is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for AQST.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
AQST vs ACB Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, ACB has a market cap of 251.3M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while ACB trades at $3.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas ACB's P/E ratio is -2.87. In terms of profitability, AQST's ROE is +2.44%, compared to ACB's ROE of -0.21%. Regarding short-term risk, AQST is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for AQST.Check ACB's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
AQST vs LFCR Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, LFCR has a market cap of 242.4M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while LFCR trades at $6.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas LFCR's P/E ratio is -5.04. In terms of profitability, AQST's ROE is +2.44%, compared to LFCR's ROE of -3.77%. Regarding short-term risk, AQST is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for AQST.Check LFCR's competition here
Shineco, Inc. (NASDAQ: TYHT)
AQST vs TYHT Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas TYHT's P/E ratio is -1.61. In terms of profitability, AQST's ROE is +2.44%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, AQST is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for AQST.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
AQST vs SIGA Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, SIGA has a market cap of 225.6M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while SIGA trades at $3.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas SIGA's P/E ratio is 11.63. In terms of profitability, AQST's ROE is +2.44%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, AQST is more volatile compared to SIGA. This indicates higher risk in terms of short-term price fluctuations for AQST.Check SIGA's competition here
Glass House Brands Inc (NYSE: GLAS)
AQST vs GLAS Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, GLAS has a market cap of 214.7M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while GLAS trades at $2.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas GLAS's P/E ratio is -4.36. In terms of profitability, AQST's ROE is +2.44%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, AQST is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for AQST.Check GLAS's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
AQST vs REPH Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas REPH's P/E ratio is -8.04. In terms of profitability, AQST's ROE is +2.44%, compared to REPH's ROE of -0.22%. Regarding short-term risk, AQST is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for AQST.Check REPH's competition here
Theratechnologies Inc. (NASDAQ: THTX)
AQST vs THTX Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas THTX's P/E ratio is -28.83. In terms of profitability, AQST's ROE is +2.44%, compared to THTX's ROE of +0.36%. Regarding short-term risk, AQST is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for AQST.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
AQST vs ASRT Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas ASRT's P/E ratio is -7.10. In terms of profitability, AQST's ROE is +2.44%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, AQST is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for AQST.Check ASRT's competition here
Journey Medical Corporation (NASDAQ: DERM)
AQST vs DERM Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, DERM has a market cap of 146.2M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while DERM trades at $5.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas DERM's P/E ratio is -23.55. In terms of profitability, AQST's ROE is +2.44%, compared to DERM's ROE of -0.20%. Regarding short-term risk, AQST is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for AQST.Check DERM's competition here
Organigram Global Inc. (NASDAQ: OGI)
AQST vs OGI Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, OGI has a market cap of 133.3M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while OGI trades at $0.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas OGI's P/E ratio is 2.12. In terms of profitability, AQST's ROE is +2.44%, compared to OGI's ROE of +0.21%. Regarding short-term risk, AQST is more volatile compared to OGI. This indicates higher risk in terms of short-term price fluctuations for AQST.Check OGI's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
AQST vs CRDL Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, CRDL has a market cap of 132.7M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while CRDL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas CRDL's P/E ratio is -4.38. In terms of profitability, AQST's ROE is +2.44%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, AQST is more volatile compared to CRDL. This indicates higher risk in terms of short-term price fluctuations for AQST.Check CRDL's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
AQST vs ORGO Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, ORGO has a market cap of 131.2M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while ORGO trades at $1.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas ORGO's P/E ratio is 34.00. In terms of profitability, AQST's ROE is +2.44%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, AQST is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for AQST.Check ORGO's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
AQST vs SCTL Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas SCTL's P/E ratio is -7.86. In terms of profitability, AQST's ROE is +2.44%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, AQST is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for AQST.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
AQST vs BGM Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, BGM has a market cap of 108.3M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while BGM trades at $8.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas BGM's P/E ratio is -1.78. In terms of profitability, AQST's ROE is +2.44%, compared to BGM's ROE of -0.05%. Regarding short-term risk, AQST is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for AQST.Check BGM's competition here
Procaps Group S.A. (NASDAQ: PROC)
AQST vs PROC Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas PROC's P/E ratio is 1.53. In terms of profitability, AQST's ROE is +2.44%, compared to PROC's ROE of -2.22%. Regarding short-term risk, AQST is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for AQST.Check PROC's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
AQST vs CPIX Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, CPIX has a market cap of 100.7M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while CPIX trades at $6.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas CPIX's P/E ratio is -16.80. In terms of profitability, AQST's ROE is +2.44%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, AQST is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for AQST.Check CPIX's competition here
OptiNose, Inc. (NASDAQ: OPTN)
AQST vs OPTN Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas OPTN's P/E ratio is -4.42. In terms of profitability, AQST's ROE is +2.44%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, AQST is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for AQST.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
AQST vs ZOM Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas ZOM's P/E ratio is -1.62. In terms of profitability, AQST's ROE is +2.44%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, AQST is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for AQST.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
AQST vs GRVI Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas GRVI's P/E ratio is 26.05. In terms of profitability, AQST's ROE is +2.44%, compared to GRVI's ROE of -4.51%. Regarding short-term risk, AQST is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for AQST.Check GRVI's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
AQST vs ZYNE Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, AQST's ROE is +2.44%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, AQST is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for AQST.Check ZYNE's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
AQST vs ZYBT Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, ZYBT has a market cap of 69.7M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while ZYBT trades at $1.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas ZYBT's P/E ratio is -7.35. In terms of profitability, AQST's ROE is +2.44%, compared to ZYBT's ROE of -0.31%. Regarding short-term risk, AQST is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for AQST.Check ZYBT's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
AQST vs SSIC Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas SSIC's P/E ratio is 11.93. In terms of profitability, AQST's ROE is +2.44%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, AQST is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for AQST.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
AQST vs VLNS Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas VLNS's P/E ratio is -1.03. In terms of profitability, AQST's ROE is +2.44%, compared to VLNS's ROE of N/A. Regarding short-term risk, AQST is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for AQST.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
AQST vs DRRX Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas DRRX's P/E ratio is -4.44. In terms of profitability, AQST's ROE is +2.44%, compared to DRRX's ROE of -0.70%. Regarding short-term risk, AQST is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for AQST.Check DRRX's competition here
Talphera, Inc. (NASDAQ: TLPH)
AQST vs TLPH Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, TLPH has a market cap of 56.1M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while TLPH trades at $1.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas TLPH's P/E ratio is -4.00. In terms of profitability, AQST's ROE is +2.44%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, AQST is more volatile compared to TLPH. This indicates higher risk in terms of short-term price fluctuations for AQST.Check TLPH's competition here
InterCure Ltd. (NASDAQ: INCR)
AQST vs INCR Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, INCR has a market cap of 52.8M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while INCR trades at $4.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas INCR's P/E ratio is -4.69. In terms of profitability, AQST's ROE is +2.44%, compared to INCR's ROE of -0.09%. Regarding short-term risk, AQST is more volatile compared to INCR. This indicates higher risk in terms of short-term price fluctuations for AQST.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
AQST vs JUPW Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas JUPW's P/E ratio is -2.41. In terms of profitability, AQST's ROE is +2.44%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, AQST is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for AQST.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
AQST vs QLI Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas QLI's P/E ratio is -4.92. In terms of profitability, AQST's ROE is +2.44%, compared to QLI's ROE of -0.16%. Regarding short-term risk, AQST is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for AQST.Check QLI's competition here
HEXO Corp. (NASDAQ: HEXO)
AQST vs HEXO Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas HEXO's P/E ratio is -0.26. In terms of profitability, AQST's ROE is +2.44%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, AQST is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for AQST.Check HEXO's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
AQST vs RMTI Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, RMTI has a market cap of 30.3M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while RMTI trades at $7.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas RMTI's P/E ratio is -5.61. In terms of profitability, AQST's ROE is +2.44%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, AQST is more volatile compared to RMTI. This indicates higher risk in terms of short-term price fluctuations for AQST.Check RMTI's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
AQST vs CPHI Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, CPHI has a market cap of 29.5M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while CPHI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas CPHI's P/E ratio is -1.59. In terms of profitability, AQST's ROE is +2.44%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, AQST is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for AQST.Check CPHI's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
AQST vs CYTH Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas CYTH's P/E ratio is -0.80. In terms of profitability, AQST's ROE is +2.44%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, AQST is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for AQST.Check CYTH's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
AQST vs SHPH Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, SHPH has a market cap of 22.7M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while SHPH trades at $4.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas SHPH's P/E ratio is -0.22. In terms of profitability, AQST's ROE is +2.44%, compared to SHPH's ROE of -1.57%. Regarding short-term risk, AQST is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for AQST.Check SHPH's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
AQST vs TXMD Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, TXMD has a market cap of 21.5M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while TXMD trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas TXMD's P/E ratio is 94.83. In terms of profitability, AQST's ROE is +2.44%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, AQST is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for AQST.Check TXMD's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
AQST vs AYTU Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, AYTU has a market cap of 21.3M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while AYTU trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas AYTU's P/E ratio is -1.66. In terms of profitability, AQST's ROE is +2.44%, compared to AYTU's ROE of -0.53%. Regarding short-term risk, AQST is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for AQST.Check AYTU's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
AQST vs EVOK Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas EVOK's P/E ratio is -7.97. In terms of profitability, AQST's ROE is +2.44%, compared to EVOK's ROE of -0.70%. Regarding short-term risk, AQST is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for AQST.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
AQST vs OPTH Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, OPTH has a market cap of 18.8M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while OPTH trades at $3.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas OPTH's P/E ratio is -2.10. In terms of profitability, AQST's ROE is +2.44%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, AQST is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for AQST.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
AQST vs ACRX Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas ACRX's P/E ratio is -0.31. In terms of profitability, AQST's ROE is +2.44%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, AQST is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for AQST.Check ACRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
AQST vs CABR Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, CABR has a market cap of 10.9M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while CABR trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas CABR's P/E ratio is -1.54. In terms of profitability, AQST's ROE is +2.44%, compared to CABR's ROE of -3.86%. Regarding short-term risk, AQST is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for AQST.Check CABR's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
AQST vs AGRX Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas AGRX's P/E ratio is -0.89. In terms of profitability, AQST's ROE is +2.44%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, AQST is more volatile compared to AGRX. This indicates higher risk in terms of short-term price fluctuations for AQST.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
AQST vs NLTX Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas NLTX's P/E ratio is -0.28. In terms of profitability, AQST's ROE is +2.44%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, AQST is more volatile compared to NLTX. This indicates higher risk in terms of short-term price fluctuations for AQST.Check NLTX's competition here
InMed Pharmaceuticals Inc. (NASDAQ: INM)
AQST vs INM Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, INM has a market cap of 7.6M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while INM trades at $1.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas INM's P/E ratio is -0.45. In terms of profitability, AQST's ROE is +2.44%, compared to INM's ROE of -1.35%. Regarding short-term risk, AQST is more volatile compared to INM. This indicates higher risk in terms of short-term price fluctuations for AQST.Check INM's competition here
Lannett Company, Inc. (NYSE: LCI)
AQST vs LCI Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas LCI's P/E ratio is -0.04. In terms of profitability, AQST's ROE is +2.44%, compared to LCI's ROE of +1.66%. Regarding short-term risk, AQST is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for AQST.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
AQST vs ADMP Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas ADMP's P/E ratio is -0.08. In terms of profitability, AQST's ROE is +2.44%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, AQST is more volatile compared to ADMP. This indicates higher risk in terms of short-term price fluctuations for AQST.Check ADMP's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
AQST vs SNOA Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, SNOA has a market cap of 5.4M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while SNOA trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas SNOA's P/E ratio is -1.01. In terms of profitability, AQST's ROE is +2.44%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, AQST is more volatile compared to SNOA. This indicates higher risk in terms of short-term price fluctuations for AQST.Check SNOA's competition here
Mallinckrodt plc (AMEX: MNK)
AQST vs MNK Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas MNK's P/E ratio is -0.44. In terms of profitability, AQST's ROE is +2.44%, compared to MNK's ROE of -0.36%. Regarding short-term risk, AQST is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for AQST.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
AQST vs FLGC Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas FLGC's P/E ratio is -0.19. In terms of profitability, AQST's ROE is +2.44%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, AQST is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for AQST.Check FLGC's competition here
cbdMD, Inc. (AMEX: YCBD)
AQST vs YCBD Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, YCBD has a market cap of 4M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while YCBD trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas YCBD's P/E ratio is -0.87. In terms of profitability, AQST's ROE is +2.44%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, AQST is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for AQST.Check YCBD's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
AQST vs GELS Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, GELS has a market cap of 3.9M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while GELS trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas GELS's P/E ratio is -0.98. In terms of profitability, AQST's ROE is +2.44%, compared to GELS's ROE of -0.36%. Regarding short-term risk, AQST is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for AQST.Check GELS's competition here
Akanda Corp. (NASDAQ: AKAN)
AQST vs AKAN Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, AKAN has a market cap of 2.7M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while AKAN trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas AKAN's P/E ratio is -0.02. In terms of profitability, AQST's ROE is +2.44%, compared to AKAN's ROE of +3.92%. Regarding short-term risk, AQST is less volatile compared to AKAN. This indicates lower risk in terms of short-term price fluctuations for AQST.Check AKAN's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
AQST vs PLXP Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas PLXP's P/E ratio is -0.22. In terms of profitability, AQST's ROE is +2.44%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, AQST is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for AQST.Check PLXP's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
AQST vs UPC Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, UPC has a market cap of 2.5M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while UPC trades at $3.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas UPC's P/E ratio is -0.48. In terms of profitability, AQST's ROE is +2.44%, compared to UPC's ROE of -0.03%. Regarding short-term risk, AQST is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for AQST.Check UPC's competition here
Athenex, Inc. (NASDAQ: ATNX)
AQST vs ATNX Comparison October 2026
Aquestive Therapeutics, Inc. (NASDAQ: AQST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AQST stands at 480.7M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, AQST is priced at $3.83 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AQST currently has a P/E ratio of -5.89, whereas ATNX's P/E ratio is -0.02. In terms of profitability, AQST's ROE is +2.44%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, AQST is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for AQST.Check ATNX's competition here